The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief?

DSpace/Manakin Repository

The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Kisloff, Michelle A. en_US
dc.date.accessioned 2012-06-07T04:01:00Z
dc.date.issued 1995 en_US
dc.identifier.citation The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief? (1995 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846781
dc.description.abstract Tylenol. Advil. Monistat 7. Imodium AD. These are some of the most commonly used, widely available, and successful drugs in the United States. All of them began as drugs only available by a prescription. All of them made a successful prescription-only to over-the-counter (Rx-to-OTC) switch through the switch" mechanisms of the Food and Drug Administration (FDA). Due to the amount of money that pharmaceutical companies can make with an Rx-to-OTC switch, the FDA has received dozens of switch requests in the last few years, and it expects to receive many more in the near future. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject H2 blockers en
dc.subject HZ blockers en
dc.subject Rx to OTC en
dc.title The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T04:01:00Z

Files in this item

Files Size Format View
mkisloff.pdf 205.3Kb PDF View/Open
mkisloff.rtf 95.93Kb RTF file View/Open
mkisloff.html 64.01Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters